BioTelemetry Inc logo

BEAT - BioTelemetry Inc Share Price

$49.86 0.9  1.9%

Last Trade - 6:45pm

Mid Cap
Market Cap £1.33bn
Enterprise Value £1.43bn
Revenue £356.5m
Position in Universe 1896th / 6316
Unlock BEAT Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, BioTelemetry Inc revenues increased 9% to $113M. Net income decreased 39% to $7.1M. Revenues reflect Helathcare segment increase of 9% to $95.7M, Research segment increase of 7% to $13.8M. Net income was offset by General and administrative increase of 15% to $31.9M (expense), Sales and marketing increase of 8% to $13.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BEAT Revenue Unlock BEAT Revenue

Net Income

BEAT Net Income Unlock BEAT Revenue

Normalised EPS

BEAT Normalised EPS Unlock BEAT Revenue

PE Ratio Range

BEAT PE Ratio Range Unlock BEAT Revenue

Dividend Yield Range

BEAT Dividend Yield Range Unlock BEAT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BEAT EPS Forecasts Unlock BEAT Revenue
Profile Summary

BioTelemetry, Inc. provides monitoring services and digital population health management in a healthcare setting, medical device manufacturing and centralized laboratory services for clinical research. The Company operates in three segments: Healthcare, Technology and Research. The Healthcare segment, operating as CardioNet, LLC and Heartcare Corporation of America, Inc., is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. The Research segment, operating as Cardiocore, LLC and VirtualScopics, Inc., is engaged in laboratory services that provide cardiac monitoring, imaging services, scientific consulting and data management services for drug, medical treatment and device trials. The Technology segment, operating as Braemar Manufacturing, LLC, Universal Medical, Inc. and BioTelemetry Belgium BVBA. and BioTelemetry Technology ApS, focuses on the manufacturing, engineering and development of noninvasive cardiac monitors for healthcare companies.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated April 12, 2013
Public Since August 1, 2013
No. of Shareholders: 52
No. of Employees: 1,700
Sector Healthcare
Industry Healthcare Providers & Services
Index Nasdaq Composite , S&P 600 Small Cap , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 34,144,802
Free Float (0.0%)
Eligible for
BEAT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BEAT
Upcoming Events for BEAT
Monday 27th July, 2020 Estimate
Q2 2020 BioTelemetry Inc Earnings Release
Monday 2nd November, 2020 Estimate
Q3 2020 BioTelemetry Inc Earnings Release
Frequently Asked Questions for BioTelemetry Inc
What is the BioTelemetry Inc share price?

As of 6:45pm, shares in BioTelemetry Inc are trading at $49.86, giving the company a market capitalisation of £1.33bn. This share price information is delayed by 15 minutes.

How has the BioTelemetry Inc share price performed this year?

Shares in BioTelemetry Inc are currently trading at $49.86 and the price has moved by -1.43% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioTelemetry Inc price has moved by -9.58% over the past year.

What are the analyst and broker recommendations for BioTelemetry Inc?

Of the analysts with advisory recommendations for BioTelemetry Inc, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BioTelemetry Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will BioTelemetry Inc next release its financial results?

BioTelemetry Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the BioTelemetry Inc dividend yield?

BioTelemetry Inc does not currently pay a dividend.

Does BioTelemetry Inc pay a dividend?

BioTelemetry Inc does not currently pay a dividend.

When does BioTelemetry Inc next pay dividends?

BioTelemetry Inc does not currently pay a dividend.

How do I buy BioTelemetry Inc shares?

To buy shares in BioTelemetry Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioTelemetry Inc?

Shares in BioTelemetry Inc are currently trading at $49.86, giving the company a market capitalisation of £1.33bn.

Where are BioTelemetry Inc shares listed? Where are BioTelemetry Inc shares listed?

Here are the trading details for BioTelemetry Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BEAT
What kind of share is BioTelemetry Inc?

Based on an overall assessment of its quality, value and momentum, BioTelemetry Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioTelemetry Inc share price forecast 2020?

Shares in BioTelemetry Inc are currently priced at $49.86. At that level they are trading at 25.08% discount to the analyst consensus target price of 0.00.

Analysts covering BioTelemetry Inc currently have a consensus Earnings Per Share (EPS) forecast of 1.61 for the next financial year.

How can I tell whether the BioTelemetry Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioTelemetry Inc. Over the past six months, the relative strength of its shares against the market has been 4.52%. At the current price of $49.86, shares in BioTelemetry Inc are trading at 11.38% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioTelemetry Inc PE Ratio?

The BioTelemetry Inc PE ratio based on its reported earnings over the past 12 months is 51.86. The shares are currently trading at $49.86.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of BioTelemetry Inc?

BioTelemetry Inc's management team is headed by:

Kirk Gorman - CHM
Fred Broadway - CEX
Daniel Wisniewski - SVP
Anthony Conti - IND
Heather Getz - CFO
Joseph Capper - CEO
Laura Dietch - IND
Stephan Rietiker - DRC
Colin Hill - IND
Joseph Frick - IND
Manish Wadhwa - OTH
Andrei Stoica - CTO
Who are the major shareholders of BioTelemetry Inc?

Here are the top five shareholders of BioTelemetry Inc based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 13.84% (4.73m shares)
ArrowMark Colorado Holdings, LLC Investment Advisor/Hedge Fund
Percentage owned: 12.96% (4.43m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 11.26% (3.84m shares)
iShares Core S&P Small-Cap ETF Mutual Fund
Percentage owned: 6.04% (2.06m shares)
Vanguard Explorer Fund Mutual Fund
Percentage owned: 5.14% (1.76m shares)
Similar to BEAT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.